^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
mRNA-5671
i
Other names: mRNA-5671, mRNA 5671, V941, mRNA5671, V-941, V 941
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Moderna
Drug class:
KRAS inhibitor
Related drugs:
2years
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) (clinicaltrials.gov)
P1, N=70, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed | N=100 --> 70
Trial completion • Enrollment change • Combination therapy
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
|
KRAS mutation • EGFR mutation • EGFR positive
|
Keytruda (pembrolizumab) • mRNA-5671
almost3years
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) (clinicaltrials.gov)
P1, N=100, Active, not recruiting, Merck Sharp & Dohme Corp. | Recruiting --> Active, not recruiting | Trial completion date: May 2025 --> Aug 2022 | Trial primary completion date: May 2025 --> Aug 2022
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
|
KRAS mutation • EGFR mutation
|
Keytruda (pembrolizumab) • mRNA-5671
3years
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) (clinicaltrials.gov)
P1, N=100, Recruiting, Merck Sharp & Dohme Corp. | Trial completion date: Nov 2026 --> May 2025 | Trial primary completion date: Nov 2026 --> May 2025
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
|
KRAS mutation • EGFR mutation
|
Keytruda (pembrolizumab) • mRNA-5671
over4years
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) (clinicaltrials.gov)
P1, N=100, Recruiting, Merck Sharp & Dohme Corp. | Trial completion date: Mar 2022 --> May 2024 | Trial primary completion date: Jun 2021 --> May 2024
Clinical • Trial completion date • Trial primary completion date • Combination therapy • PD(L)-1 Biomarker
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
|
KRAS mutation • EGFR mutation
|
Keytruda (pembrolizumab) • mRNA-5671
Share via
